University of Louisville Journal of Respiratory Infections

CASE REPORT

RSV-induced Guillain–Barré Syndrome: A Case Report
Priyanga Jayakumar1 , MD; Christie Shen2 , MD; Dylan Goldsmith3 ; Steven Lippmann4∗ , MD
1

Scott and White Medical Centre, Texas A&M, Round Rock, TX, USA; 2 Family Medicine, Scott and White Medical Centre, Texas A&M, Round Rock, TX, USA;
School of Medicine, University of Louisville, Louisville, KY, USA; 4 Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Louisville,
Louisville, KY, USA
3

∗

steven.lippmann@louisville.edu

Recommended Citation: Jayakumar P, Shen C, Goldsmith D, Lippman S. RSV-induced Guillain-Barré syndrome: A case report. Univ Louisville J Respir Infect
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Abstract
A patient with a respiratory syncytial virus-induced Guillain–
Barré Syndrome and acute disseminated encephalomyelitis
is presented. This virus is the most common cause of upper
respiratory infections, and it can become an etiology for ex-

trapulmonary pathology with serious complications. Although
rare, the possibility of adverse comorbidities makes early diagnosis and treatment of these cases critical.

Introduction

Case Description

Guillain–Barré syndrome is characterized by weakness,
numbness, and paresthesia in peripheral and cranial
nerve-innervated musculature.[1] It often affects people following bacterial or viral infection with an autoimmune process, inducing demyelination and axonal
damage.[2] The annual US incidence of Guillain–Barré
syndrome is 1.2–3 per 100,000 inhabitants.[3] Approximately two-thirds of cases follow upper respiratory
infections or diarrhea, 30 percent are subsequent to
Campylobacter jejuni, and 10 percent are induced by cytomegalovirus.[4, 5] As of July 2021, over 100 cases
of Guillain–Barré syndrome have been reported to the
Vaccine Adverse Event Reporting System (VAERS) in
recipients of the Ad26.COV2.S vaccine (developed by
Johnson & Johnson) among 12.5 million doses administered in the US.[6]

A 44-year-old man presented to the emergency department with a one-month history of intermittent
fever, cough, and congestion. After remission of
his symptoms, he visited Spain and India for a few
weeks; his symptoms re-emerged upon returning to
the United States. Unspecified antibiotic, steroid, and
bronchodilator therapies were prescribed for upper respiratory infection but were ineffective. He felt worse,
experiencing fatigue, malaise, headache, and gait imbalance. A blurry vision emerged in his right eye, accompanied by pain with extraocular movements. Initially, an emergency department evaluation was inconclusive, including a normal complete blood count,
metabolic panel, and erythrocyte sedimentation rate.
The computerized tomographic (CT) image of the orbit and head CT angiogram were remarkable for left
maxillary sinusitis. This condition was managed with
antibiotics and pain medications. The patient was referred to the ophthalmology clinic, where binocular
diplopia was documented.

Respiratory syncytial virus (RSV) infections commonly
cause seasonal outbreaks of respiratory illness in persons of all ages. Those considered high-risk populations experience increased incidences of mortality.
These high-risk populations include infants, young
children, adults with chronic medical conditions, and
older adults.[7, 8] Although RSV commonly affects the
lungs, extrapulmonary pathologies may also occur in
these high-risk populations. Extrapulmonary complications may occur in the brain, liver, heart, and kidneys.[9]
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Over the next two days, his condition worsened with
slurred speech, numbness in the face and extremities,
and difficulty voiding. The patient was hospitalized,
where he exhibited several neurologic deficits, including orbicularis oculi and oris weakness, bilateral intrinsic hand muscle weakness, dyscoordination, and diminished sensation in the hands and feet. The presumptive diagnosis was meningitis, for which antiviral
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Figure 1. Initial magnetic resonance imaging of the brain.

Figure 2. Magnetic resonance imaging of the brain evidencing abnormal findings two months after initial presentation.

and antibiotic drugs (acyclovir, ceftriaxone, and vancomycin) were prescribed.

bladder function during the next week and improved
his diplopia and fatigue with persisting leg numbness.
Still improving, he was discharged to a rehabilitation
facility.

Laboratory results, including complete blood count,
metabolic panel, vitamin B12 level, thyroid-stimulating
hormone, creatinine kinase, and blood cultures, were
unremarkable. Screening for syphilis, human immunodeficiency virus, and West Nile were routine, as
were a meningitis/encephalitis serum panel and an
immunofixation ganglioside antibody panel. A cerebrospinal fluid study was negative for cultures, glucose
concentration, and antinuclear antibodies. Testing for
RSV was positive. Reimaging confirmed the left maxillary sinusitis. Magnetic resonance imaging (MRI) of
the brain (Figure 1) was performed. MRI of the thoracic spine revealed leptomeningeal enhancement and
degenerative changes in the lumbar region, two nonspecific findings indicating possible pathology. Since
meningitis was deemed unlikely by brain MRI, antibiotic and antiviral drugs were discontinued.
A diagnosis of Guillain–Barré syndrome secondary to
the respiratory syncytial virus was made at this time.
The patient then received treated with intravenous
immunoglobulin (IVIG), 1 g/kg. Within two days,
there was an improvement—especially in ocular motor strength. However, he also developed hiccups, sinus pauses, and bradycardia, presumably secondary to
autonomic nervous system involvement. He regained
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After two months, the patient was re-hospitalized due
to more urinary retention, paresthesia, ataxia, and hiccups. On physical examination, a decreased sensation
was noted in all extremities. Additionally, dermatomal
thoracic pain and sensory loss across the abdomen and
both arms were also noted. A chronic inflammatory demyelinating polyradiculoneuropathy was among the
differential considerations, and IVIG therapy continued. MRI of the brain (Figure 2) demonstrated an expansile abnormality of the medial left temporal lobe, bilateral caudate nuclei, bilateral thalami, left basal ganglia, and left ventral midbrain; these findings were
not visualized in previous imaging. These abnormalities were consistent with acute disseminated encephalomyelitis. The patient responded to treatment
with IVIG as his hiccups, urinary retention, and paresthesia continued to resolve.
Further workup was performed. Electromyography
was normal. Numerous markers of autoimmune processes were within normal limits, such as neuromyelitis
optica (NMO) Aquaporin-4 Receptor Antibody (AQP4Abs), myelin-associated glycoprotein immunoglobulin
(MAG(Ig)M), myelin-oligodendrocyte glycoprotein an-
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Figure 3. Follow-up magnetic resonance imaging of the brain.

tibodies (MOG-Abs), B-lymphocyte antigen CD20 (CD
20), thiopurine methyltransferase tests, antinuclear antibodies, and antithyroid antibodies. However, the glutamic acid decarboxylase 65, a common marker of type
1 diabetes mellitus, was elevated to 0.07 nmol/L. Moreover, the anti-GD1a antibody, a marker of numerous
motor syndromes, was elevated to 64 u/L.
At two and five months, MRIs were performed and
demonstrated complete resolution of the spinal and
brain lesions (Figure 3). Clinically, the patient has
remained asymptomatic for over a year. The definitive diagnosis was GD1a antibody–associated RSVinduced Guillain–Barré syndrome with post-infectious
acute disseminated encephalomyelitis.

Discussion
RSV infection activates cytokines, arachidonic acid,
interleukins, tumor necrosis factor, and plateletactivating factors. The etiology of neural disruption
remains unclear; however, it has been proposed that
these inflammatory mediators may play a significant
role in this process.[10] Associations between RSV and
Guillain–Barré syndrome with neurologic involvement
usually occur among children.[11]
Typical features of Guillain–Barré syndrome include
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symmetrical weakness in the legs with absent or weak
deep tendon reflexes. Up to 90 percent of patients
experience paresthesia, and nearly 70 percent demonstrate dysautonomia with urinary retention. About
10 percent report weakness of extremities and up to
30 percent in respiratory musculature. Other manifestations can include facial nerve palsy, oropharyngeal or oculomotor weakness, diarrhea or constipation,
and tachycardia; hyponatremia is also observed.[12,
13] Guillain–Bárre syndrome reportedly also appears in
other variants, such as acute inflammatory demyelinating polyradiculoneuropathy, Miller Fisher syndrome,
acute motor axonal neuropathy, and acute motor and
sensory axonal neuropathy.[14]
Cerebrospinal fluid testing often helps to exclude other
etiologies rather than to confirm Guillain–Barré syndrome. Brain imaging is less valuable to assist in diagnosis. Glycolipid antibodies are not reliably diagnostic for Guillain–Barré syndrome.[12] There are various
criteria for recognizing Guillain–Barré syndrome and
its variants.[15, 16] Currently, nerve conduction studies
are the “gold standard” for diagnosing Guillain–Barré
syndrome.[17] One case report documented Guillain–
Barré syndrome caused by RSV in an 81-year-old immunocompromised woman.[18] Her illness began with
weakness and required respiratory assistance; she died
despite treatment with plasmapheresis.
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Identifying Guillain–Barré syndrome and its variants is
difficult in patients with atypical presentations.[14, 16]
Clinical features help to confirm diagnoses; there are no
diagnostic biomarkers. Early treatment is vital to mini-

mize neurological complications, including dangerous,
quickly developing apneas. Some affected individuals
require respiratory assistance. Diagnostic precision is
paramount.
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2010; 28(6):545-52. doi: 10.3329/jhpn.v28i6.6602. PMID:
21261199.
6. Coronavirus (COVID-19) Update: July 13, 2021. Online: U.S. Food & Drug Administration, 2021. Available
at: https://www.fda.gov/news-events/press-announcements/
coronavirus-covid-19-update-july-13-2021.
7. Shi T, Denouel A, Tietjen AK, et al. Global Disease Burden
Estimates of Respiratory Syncytial Virus-Associated Acute
Respiratory Infection in Older Adults in 2015: A Systematic
Review and Meta-Analysis. J Infect Dis 2020; 222(Suppl
7):S577-s83. doi: 10.1093/infdis/jiz059. PMID: 30880339.
8. Shi T, Vennard S, Mahdy S, Nair H. Risk factors for RSV
associated acute lower respiratory infection poor outcome
and mortality in young children: A systematic review and
meta-analysis. J Infect Dis 2021. doi: 10.1093/infdis/jiaa751.
PMID: 33576788.
9. Farahmand M, Shatizadeh Malekshahi S, Jabbari MR,
Shayestehpour M. The landscape of extrapulmonary manifestations of human parainfluenza viruses: A systematic
narrative review. Microbiol Immunol 2021; 65(1):1-9. doi:
10.1111/1348-0421.12865. PMID: 33270253.
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/21

10. Bohmwald K, Gálvez NMS, Canedo-Marroquı́n G, et al.
Contribution of Cytokines to Tissue Damage During Human
Respiratory Syncytial Virus Infection. Front Immunol 2019;
10:452. doi: 10.3389/fimmu.2019.00452. PMID: 30936869.
11. Robinson CP, Busl KM. Neurologic Manifestations of Severe Respiratory Viral Contagions. Crit Care Explor 2020;
2(4):e0107. doi: 10.1097/cce.0000000000000107. PMID:
32426749.
12. Anandan C, Khuder SA, Koffman BM. Prevalence of
autonomic dysfunction in hospitalized patients with GuillainBarré syndrome. Muscle Nerve 2017; 56(2):331-3. doi:
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